InMed Pharmaceuticals Inc. (INM): Price and Financial Metrics
INM Price/Volume Stats
| Current price | $0.24 | 52-week high | $2.08 |
| Prev. close | $0.26 | 52-week low | $0.23 |
| Day low | $0.24 | Volume | 142,600 |
| Day high | $0.27 | Avg. volume | 315,710 |
| 50-day MA | $0.34 | Dividend yield | N/A |
| 200-day MA | $0.53 | Market Cap | 1.47M |
INM Stock Price Chart Interactive Chart >
InMed Pharmaceuticals Inc. (INM) Company Bio
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Latest INM News From Around the Web
Below are the latest news stories about INMED PHARMACEUTICALS INC that investors may wish to consider to help them evaluate INM as an investment opportunity.
InMed Announces Results of 2023 Annual General MeetingVancouver, British Columbia--(Newsfile Corp. - December 19, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today confirmed that, at its annual general meeting of shareholders held on December 19, 2023 (the "Meeting"), all of the matters put forward before shareholders for consideration and approval as set out in InMed's notice of meeting and managemen |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayChecking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading! |
InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular DegenerationINM-089 improves retinal function in in vivo preclinical AMD disease modelEstablishes cannabinol (CBN) analog candidate in a new disease targetVancouver, British Columbia--(Newsfile Corp. - November 29, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announces the launch of INM-089, a cannabinol ("CBN") analog, to investigate i |
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business UpdateVancouver, British Columbia--(Newsfile Corp. - November 14, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today reports financial results for the first quarter of the fiscal year 2024 which ended September 30, 2023.The Company's full financial statements and related MD&A for the first quarter ended September 30, 2023, are available |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a hot topic on Wednesday and we're starting the morning with a breakdown of the biggest ones. |
INM Price Returns
| 1-mo | -25.47% |
| 3-mo | -26.70% |
| 6-mo | -42.83% |
| 1-year | -80.49% |
| 3-year | -99.72% |
| 5-year | N/A |
| YTD | -42.31% |
| 2023 | -79.41% |
| 2022 | -93.83% |
| 2021 | -60.18% |
| 2020 | -44.61% |
| 2019 | N/A |
Loading social stream, please wait...